Company intelligence / Profile preview
Epicrispr Biotechnologies
South San Francisco, California, United Statesepicrispr.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Epicrispr’s lead program EPI-321 is entering Phase 1 clinical trials in New Zealand for FSHD after receiving FDA IND clearance. Preclinical data show robust suppression of DUX4 expression and muscle protection. The therapy has received Fast Track, Rare Pediatric Disease, and Orphan Drug designations from the FDA. Other pipeline programs remain at the preclinical stage.
- Therapeutic areas
- Metabolic DisordersOncologyRare DiseasesHematologyOphthalmology
- Modalities
- Epigenetic modulationGene expression modulationCRISPR-based gene regulation (non-cutting, dCas proteins)AAV-delivered gene therapies
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
Request access →03
Partnerships
Kite Pharma/Gilead Sciences – research collaboration to develop next-generation CAR T-cell therapies using GEMS platform technology.SOLVE FSHD – advocacy/investor partnership focused on FSHD clinical development funding.Ally Bridge Group – lead investor with strategic involvement.
Beyond the preview
Go deeper on Epicrispr Biotechnologies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Epicrispr Biotechnologies.